Amantadine Hcl

證據等級: L5

預測適應症: 0 個

Amantadine HCl: Repurposing Evaluation — Insufficient Data to Proceed

One-Sentence Summary

Amantadine HCl is a well-known antiviral and antiparkinsonian agent used clinically for influenza A prophylaxis and Parkinson's disease management. However, this Evidence Pack contains no predicted repurposing indications from TxGNN, and key data items — including the mechanism of action, Singapore market registration, and safety warnings — are all unresolved gaps. A meaningful repurposing evaluation cannot be completed until these gaps are addressed.

Quick Overview

Item	Content
Original Indication	Not recorded in this Evidence Pack
Predicted New Indication	None — TxGNN predictions not available
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction unavailable; no supporting studies retrievable)
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

This section cannot be completed as written because the Evidence Pack contains no predicted indication (predicted_indications: []). There is therefore no mechanistic link to evaluate between a source and target disease.

From publicly available pharmacological knowledge, Amantadine HCl is understood to act as an NMDA receptor antagonist and dopamine-releasing agent. It has established use in influenza A prophylaxis and Parkinson's disease. These mechanisms have led researchers to investigate it in conditions such as fatigue syndromes, traumatic brain injury, and multiple sclerosis — but none of these directions is reflected in this Evidence Pack, and none can be formally evaluated here without TxGNN predictions and supporting evidence data.

Until a complete Evidence Pack with predicted_indications is generated, mechanistic reasoning for repurposing cannot be substantiated.

Clinical Trial Evidence

Currently no related clinical trials are registered in this Evidence Pack.

Literature Evidence

Currently no related literature is available in this Evidence Pack.

Singapore Market Information

Amantadine HCl holds zero active product licences in Singapore. The drug is classified as not marketed.

There are no registration records to display.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields in this Evidence Pack — including key warnings, contraindications, and drug–drug interactions — returned no data. The DDI query status is not_found with zero interactions recorded. The TFDA package insert has not been parsed (Data Gap DG001, severity: Blocking).

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is structurally incomplete: there are no predicted indications, no regulatory registrations, no safety data, and no mechanistic information. Proceeding to any repurposing evaluation stage is not possible in this state.

To proceed, the following is needed:

[DG001 — Blocking] Obtain and parse the package insert (仿單) from the TFDA website to extract warnings and contraindications. Without this, the safety screening step (S1) cannot begin.
[DG002 — High] Retrieve the mechanism of action via the DrugBank API using the DrugBank ID. The ID field is currently null — a successful DrugBank query was logged (Query ID 2, status: success), but the result was not written back into the pack.
Re-run TxGNN prediction pipeline — the predicted_indications array is empty, which means either the drug was not matched to a DrugBank node or the pipeline did not execute. Confirm DrugBank ID resolution and rerun repurposing scoring.
Confirm INN standardisation — the drug is listed as AMANTADINE HCL (salt form). Verify that the mapping pipeline is correctly resolving this to the base INN amantadine before querying DrugBank and TxGNN.
Once predictions are available, re-generate a full Evidence Pack and re-evaluate using the standard L1–L5 evidence framework.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.